| gefitinib / Generic mfg. |
NCT00066339: Gefitinib in Treating Patients With Metastatic Breast Cancer That Has Progressed After Antiestrogen and Nonsteroidal Aromatase Inhibitor Therapy |
|
|
| Completed | 2 | 44 | Europe | gefitinib | European Organisation for Research and Treatment of Cancer - EORTC | Breast Cancer | 01/04 | | | |
NCT00082667: Gefitinib Followed By Surgery in Treating Women With Ductal Carcinoma In Situ of the Breast |
|
|
| Terminated | 2 | 1 | US | gefitinib, ZD 1839, Iressa, Surgery, lumpectomy or mastectomy of the breast | Vanderbilt-Ingram Cancer Center, National Cancer Institute (NCI) | Breast Cancer | 07/04 | 06/05 | | |
| Completed | 2 | 65 | US, Canada, Europe, RoW | Gefitinib | AstraZeneca, Cancer International Research Group (CIRG) | Breast Cancer | | 02/05 | | |
NCT00080743: Gefitinib With or Without Tamoxifen in Treating Patients With Tamoxifen-Resistant Metastatic Breast Cancer |
|
|
| Completed | 2 | 2 | US | gefitinib, ZD1839, Iressa, tamoxifen citrate, Nolvadex, Placebo, Sugar pill | Dartmouth-Hitchcock Medical Center, National Cancer Institute (NCI), Norris Cotton Cancer Center | Breast Cancer | 04/05 | 11/05 | | |
NCT00247481: ZD1839 (Iressa™) In Combination With Docetaxel As First-Line Treatment In Patients With Metastatic Breast Cancer |
|
|
| Completed | 2 | 77 | Europe | Gefitinib, Docetaxel | AstraZeneca | Breast Cancer | | 06/05 | | |
| Completed | 2 | 54 | Europe | gefitinib (IRESSA™, ZD1839), IRESSA™, ZD1839 | AstraZeneca | Breast Cancer | | 10/05 | | |
NCT00255463: Phase II Neoadjuvant ER+/PgR + Arimidex +/- Iressa Study |
|
|
| Completed | 2 | 185 | Europe | Anastrazole, Gefitinib | AstraZeneca | Breast Cancer | | 11/05 | | |
NCT00319618: Combination Weekly Taxotere™ With Iressa™ /Placebo in Metastatic Breast Cancer |
|
|
| Completed | 2 | 66 | Europe | Gefitinib, Docetaxel | AstraZeneca | Metastatic Breast Cancer | | 06/06 | | |
|
NCT00052169: Therapy With Docetaxel and ZD1839 for Patients Who Have Advanced Breast Cancer |
|
|
| Completed | 2 | 33 | US | ZD1839 in combination with docetaxel, Docetaxel (Taxotere), ZD1839, gefitinib (Iressa) | NSABP Foundation Inc, AstraZeneca | Breast Neoplasms | | 09/06 | | |
NCT00206414: Arimidex/Faslodex/Iressa Study: A Trial Using Arimidex, Faslodex and Iressa in Women With Breast Cancer |
|
|
| Terminated | 2 | 15 | US | Iressa Day 1 given with Arimidex and Faslodex, gefitinib, Iressa Day 21 given with Arimidex and Faslodex, gefitninb | Baylor Breast Care Center | BREAST CANCER | 09/06 | 09/06 | | |
NCT00206492: Trial of ZD1839 (Iressa) and Tamoxifen in Breast Cancer Patients |
|
|
| Terminated | 2 | 3 | US | Iressa, ZD1839, Tamoxifen | Baylor Breast Care Center, AstraZeneca | Breast Cancer | 10/06 | 10/06 | | |
NCT00229697: Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa Study |
|
|
| Completed | 2 | 317 | US, Canada, Europe, RoW | Gefitinib, Iressa, Tamoxifen, Nolvadex | AstraZeneca | Breast Neoplasms | 12/06 | 06/15 | | |
NCT00239343: Phase II Trial of Preoperative Therapy With Gefitinib and Chemotherapy in Patients With ERneg Breast Cancer |
|
|
| Completed | 2 | 160 | Europe | gefitinib | AstraZeneca | Breast Cancer | 05/07 | 05/07 | | |
NCT00024154: Trastuzumab and Gefitinib in Treating Patients With Metastatic Breast Cancer |
|
|
| Completed | 2 | 132 | US | trastuzumab, anti-c-erB-2, Herceptin, MOAB HER2, gefitinib, Iressa, ZD 1839, laboratory biomarker analysis | National Cancer Institute (NCI) | Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer | 07/07 | | | |
NCT00066378: Anastrozole With or Without Gefitinib in Treating Postmenopausal Women With Metastatic or Locally Recurrent Breast Cancer |
|
|
| Completed | 2 | 71 | Europe | anastrozole, gefitinib | European Organisation for Research and Treatment of Cancer - EORTC | Breast Cancer | 08/07 | | | |
NCT00049062: Anastrozole and ZD 1839 in Treating Postmenopausal Women With Metastatic Breast Cancer |
|
|
| Completed | 2 | | US | anastrozole, gefitinib | The University of Texas Health Science Center at San Antonio | Breast Cancer | 10/07 | 10/07 | | |
NCT00234403: A Trial to Evaluate the Combination of Iressa & Faslodex® in Patients With Advanced or Metastatic Breast Cancer |
|
|
| Completed | 2 | 60 | Europe | gefitinib and fulvestrant | AstraZeneca | Breast Cancer | | 10/07 | | |
NCT00428896: A Feasibility Study With Iressa in Resistant Cytokeratin-Positive Tumor Cells Circulating in the Blood of Women With Breast Cancer |
|
|
| Completed | 2 | 24 | Europe | ZD1839, Iressa | University Hospital of Crete | Breast Cancer | 03/08 | 03/08 | | |
NCT00252811: A Study of ZD1839 Effects on Cell Proliferation in Breast Cancer |
|
|
| Withdrawn | 2 | 60 | Europe | Gefitinib | AstraZeneca | Breast Cancer | | | | |
NCT00057941: Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer |
|
|
| Completed | 2 | 148 | US | anastrozole, ANAS, Arimidex, ICI-D1033, gefitinib, Iressa, ZD 1839, fulvestrant, Faslodex, ICI 182,780, laboratory biomarker analysis | National Cancer Institute (NCI) | Estrogen Receptor-positive Breast Cancer, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer | 06/12 | 06/12 | | |
|
NCT00054691: ZD1839 (Iressa) for Recurrent or Metastatic Squamous Cell Carcinoma of the Skin |
|
|
| Completed | 2 | 40 | US | Iressa, ZD1839, Gefitinib | M.D. Anderson Cancer Center, AstraZeneca | Skin Cancer | 10/12 | 10/12 | | |
NCT00077025: Comparing Anastrozole-Placebo to the Combination Anastrozole-ZD1839 in Postmenopausal Patients With Estrogen Receptor and/or Progesterone Receptor Metastatic Breast Cancer |
|
|
| Completed | 2 | 174 | US, RoW | Gefitinib, IRESSA, Anastrozole, Arimidex | AstraZeneca | Breast Cancer | 05/13 | 05/13 | | |
NCT00086957: Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast Cancer |
|
|
| Completed | 1/2 | 31 | US | trastuzumab, docetaxel, gefitinib | City of Hope Medical Center, National Cancer Institute (NCI) | Breast Cancer | 08/15 | 08/15 | | |
